Clinical, Laboratorial, and Urodynamic Findings of Prostatic Artery Embolization for the Treatment of Urinary Retention Related to Benign Prostatic Hyperplasia. A Prospective Single-Center Pilot Study

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorANTUNES, Alberto A.
dc.contributor.authorCARNEVALE, Francisco C.
dc.contributor.authorLEAL FILHO, Joaquim M. da Motta
dc.contributor.authorYOSHINAGA, Eduardo M.
dc.contributor.authorCERRI, Luciana M. O.
dc.contributor.authorBARONI, Ronaldo H.
dc.contributor.authorMARCELINO, Antonio S. Z.
dc.contributor.authorCERRI, Giovanni G.
dc.contributor.authorSROUGI, Miguel
dc.date.accessioned2013-09-23T16:37:36Z
dc.date.available2013-09-23T16:37:36Z
dc.date.issued2013
dc.description.abstractThis study was designed to describe the clinical, laboratorial, and urodynamic findings of prostatic artery embolization (PAE) in patients with urinary retention due to benign prostatic hyperplasia (BPH). A prospective study of 11 patients with urinary retention due to BPH was conducted. Patients underwent physical examination, prostate specific antigen (PSA) measurement, transrectal ultrasound, and magnetic resonance imaging. International prostate symptom score (IPSS), quality of life (QoL), and urodynamic testing were used to assess the outcome before and after 1 year. Clinical success was 91 % (10/11 patients) with a mean follow-up of 22.3 months (range, 12-41 months). At the first year follow-up, the mean IPSS score was 2.8 points (p = 0.04), mean QoL was 0.4 points (p = 0.001), mean PSA decreased from 10.1 to 4.3 ng/mL (p = 0.003), maximum urinary flow (Qmax) improved from 4.2 to 10.8 mL/sec (p = 0.009), and detrusor pressure (Pdet) decreased from 85.7 to 51.5 cm H2O (p = 0.007). Before PAE, Bladder Outlet Obstruction Index (BOOI) showed values > 40 in 100 % of patients. After PAE, 30 % of patients were > 40 (obstructed), 40 % were between 20 and 40 (undetermined), and 30 % were < 20 (unobstructed). Patients with a BOOI < 20 had higher PSA values at 1-day after PAE. Clinical and urodynamic parameters improved significantly after PAE in patients with acute urinary retention due to BPH. Total PSA at day 1 after PAE was higher in patients with unobstructed values in pressure flow studies.
dc.description.indexMEDLINE
dc.identifier.citationCARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, v.36, n.4, p.978-986, 2013
dc.identifier.doi10.1007/s00270-013-0611-5
dc.identifier.issn0174-1551
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1897
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofCardiovascular and Interventional Radiology
dc.rightsrestrictedAccess
dc.rights.holderCopyright SPRINGER
dc.subjectClinical practice
dc.subjectImaging
dc.subjectArterial intervention
dc.subjectEmbolization/embolisation/embolotherapy
dc.subjectEndovascular treatment
dc.subjectTranscatheter therapy
dc.subjectMRI/MRA
dc.subjectProstate
dc.subjectUrinary tract
dc.subject.otherbladder outlet obstruction
dc.subject.othertransurethral resection
dc.subject.othermassive hematuria
dc.subject.otherfollow-up
dc.subject.othermanagement
dc.subject.otherhemorrhage
dc.subject.othersape
dc.subject.otherturp
dc.subject.wosCardiac & Cardiovascular Systems
dc.subject.wosRadiology, Nuclear Medicine & Medical Imaging
dc.titleClinical, Laboratorial, and Urodynamic Findings of Prostatic Artery Embolization for the Treatment of Urinary Retention Related to Benign Prostatic Hyperplasia. A Prospective Single-Center Pilot Study
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus79
hcfmusp.contributor.author-fmusphcALBERTO AZOUBEL ANTUNES
hcfmusp.contributor.author-fmusphcFRANCISCO CESAR CARNEVALE
hcfmusp.contributor.author-fmusphcJOAQUIM MAURICIO DA MOTTA LEAL FILHO
hcfmusp.contributor.author-fmusphcEDUARDO MURACCA YOSHINAGA
hcfmusp.contributor.author-fmusphcLUCIANA MENDES DE OLIVEIRA CERRI
hcfmusp.contributor.author-fmusphcRONALDO HUEB BARONI
hcfmusp.contributor.author-fmusphcANTONIO SERGIO ZAFRED MARCELINO
hcfmusp.contributor.author-fmusphcGIOVANNI GUIDO CERRI
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.description.beginpage978
hcfmusp.description.endpage986
hcfmusp.description.issue4
hcfmusp.description.volume36
hcfmusp.origemWOS
hcfmusp.origem.pubmed23580116
hcfmusp.origem.scopus2-s2.0-84879898557
hcfmusp.origem.wosWOS:000321265000015
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAbrams P, 1999, BJU INT, V84, P14
hcfmusp.relation.referenceAntunes Alberto Azoubel, 2006, Clinics (Sao Paulo), V61, P545, DOI 10.1590/S1807-59322006000600010
hcfmusp.relation.referenceAPPLETON DS, 1988, BRIT J UROL, V61, P45, DOI 10.1111/j.1464-410X.1988.tb09160.x
hcfmusp.relation.referenceBarbieri A, 2002, UROL INT, V69, P318, DOI 10.1159/000066115
hcfmusp.relation.referenceBISCHOFF W, 1977, UROLOGE A, V16, P99
hcfmusp.relation.referenceCarnevale FC, 2011, CARDIOVASC INTER RAD, V34, P1330, DOI 10.1007/s00270-011-0136-8
hcfmusp.relation.referenceCarnevale FC, 2010, CARDIOVASC INTER RAD, V33, P355, DOI 10.1007/s00270-009-9727-z
hcfmusp.relation.referenceCarnevale FC, 2013, J VASC INTERV RADIOL, V24, P535, DOI 10.1016/j.jvir.2012.12.019
hcfmusp.relation.referenceCross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
hcfmusp.relation.referenceDeMeritt JS, 2000, J VASC INTERV RADIOL, V11, P767, DOI 10.1016/S1051-0443(07)61638-8
hcfmusp.relation.referenceJeon GS, 2009, J VASC INTERV RADIOL, V20, P384, DOI 10.1016/j.jvir.2008.11.014
hcfmusp.relation.referenceMadersbacher S, 2004, EUR UROL, V46, P547, DOI 10.1016/j.eururo.2004.07.016
hcfmusp.relation.referenceMcVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074
hcfmusp.relation.referenceMcVary KT, 2006, AM J MANAG CARE, V12, P122
hcfmusp.relation.referenceMichel F, 2002, J UROLOGY, V168, P2550, DOI 10.1097/01.ju.0000036371.49460.7d
hcfmusp.relation.referenceMilord RA, 2000, AM J SURG PATHOL, V24, P1378, DOI 10.1097/00000478-200010000-00007
hcfmusp.relation.referenceMITCHELL ME, 1976, J UROLOGY, V115, P692
hcfmusp.relation.referenceMuzzonigro G, 2004, J UROLOGY, V172, P611, DOI 10.1097/01.ju.0000131258.36966.dI
hcfmusp.relation.referenceNadalini V F, 1981, Radiol Med, V67, P61
hcfmusp.relation.referencePisco JM, 2011, J VASC INTERV RADIOL, V22, P11, DOI 10.1016/j.jvir.2010.09.030
hcfmusp.relation.referenceRassweiler J, 2006, EUR UROL, V50, P969, DOI 10.1016/j.eururo.2005.12.042
hcfmusp.relation.referenceRastinehad AR, 2008, UROLOGY, V71, P181, DOI 10.1016/j.urology.2007.09.012
hcfmusp.relation.referenceSchafer W, 2002, NEUROUROL URODYNAM, V21, P261, DOI 10.1002/nau.10066
hcfmusp.relation.referenceSun F, 2008, RADIOLOGY, V246, P783, DOI 10.1148/radiol.2463070647
hcfmusp.relation.referenceTan L, 2009, NAT REV UROL, V6, P680, DOI 10.1038/nrurol.2009.215
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication1e8c7153-c3dc-4c8f-8bf8-5e004f275e35
relation.isAuthorOfPublication2ce53f16-d56a-4243-bb83-8fbac9c3189e
relation.isAuthorOfPublication1e71ee13-4ae0-4128-8b3f-19fdc3c9f9b2
relation.isAuthorOfPublication9647b375-bd2a-4a6b-96ec-2658b78f13f8
relation.isAuthorOfPublication0feb5bad-7412-40af-921c-64ff5fe8ee18
relation.isAuthorOfPublication7eee5d61-7530-40cf-8ec0-b3709672d076
relation.isAuthorOfPublicationbdd72d9b-e7b3-464f-982e-33ebb3e2135e
relation.isAuthorOfPublication639bdb47-6864-4462-951e-519181ec7bfd
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication.latestForDiscovery1e8c7153-c3dc-4c8f-8bf8-5e004f275e35
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_ANTUNES_Clinical_Laboratorial_and_Urodynamic_Findings_of_Prostatic_Artery_2013.PDF
Tamanho:
494.26 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)